CR20220584A - Inhibidores de kras tricíclicos fusionados - Google Patents

Inhibidores de kras tricíclicos fusionados

Info

Publication number
CR20220584A
CR20220584A CR20220584A CR20220584A CR20220584A CR 20220584 A CR20220584 A CR 20220584A CR 20220584 A CR20220584 A CR 20220584A CR 20220584 A CR20220584 A CR 20220584A CR 20220584 A CR20220584 A CR 20220584A
Authority
CR
Costa Rica
Prior art keywords
compounds
fused tricyclic
kras inhibitors
kras
inhibitors
Prior art date
Application number
CR20220584A
Other languages
English (en)
Inventor
Wenqing Yao
Wenyu Zhu
xiaozhao Wang
Artem Shvartsbart
Rocco Policarpo
Chao Qi
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20220584A publication Critical patent/CR20220584A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se describen compuestos de la fórmula I, métodos de uso de compuestos para inhibir la actividad de KRAS y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de KRAS, como el cáncer.
CR20220584A 2020-04-16 2021-04-15 Inhibidores de kras tricíclicos fusionados CR20220584A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011089P 2020-04-16 2020-04-16
US202163146899P 2021-02-08 2021-02-08
PCT/US2021/027513 WO2021211864A1 (en) 2020-04-16 2021-04-15 Fused tricyclic kras inhibitors

Publications (1)

Publication Number Publication Date
CR20220584A true CR20220584A (es) 2023-02-15

Family

ID=75870725

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220584A CR20220584A (es) 2020-04-16 2021-04-15 Inhibidores de kras tricíclicos fusionados

Country Status (16)

Country Link
US (1) US20210355121A1 (es)
EP (1) EP4135844A1 (es)
JP (1) JP2023522202A (es)
CN (1) CN115702025A (es)
AU (1) AU2021254794A1 (es)
BR (1) BR112022020841A2 (es)
CA (1) CA3179692A1 (es)
CL (2) CL2022002828A1 (es)
CO (1) CO2022016377A2 (es)
CR (1) CR20220584A (es)
EC (1) ECSP22087539A (es)
IL (1) IL297165A (es)
MX (1) MX2022012780A (es)
PE (1) PE20230825A1 (es)
TW (1) TW202204355A (es)
WO (1) WO2021211864A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
CA3152025A1 (en) 2019-09-24 2021-04-01 David BRIERE Combination therapies
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
KR20240004960A (ko) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. Ras 억제제
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
WO2023056421A1 (en) * 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
TW202320792A (zh) 2021-11-22 2023-06-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
CN115317490A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 化合物bml-275在制备改善鼻咽癌预后的药物中的应用
CN114394967B (zh) * 2022-01-28 2023-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种2-吡唑苯胺与1,3-二羰基化合物合成吡唑并喹啉衍生物的方法
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20240101557A1 (en) * 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
KR100926194B1 (ko) 2001-10-30 2009-11-09 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의스타우로스포린 유도체
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EA007395B3 (ru) 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
CN101945867A (zh) 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
KR102097887B1 (ko) 2008-09-26 2020-04-06 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103429243B (zh) 2010-10-25 2016-06-08 G1治疗公司 Cdk抑制剂
CN102655637A (zh) * 2011-03-01 2012-09-05 中兴通讯股份有限公司 一种移动通信系统和组网方法
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
ME02394B (me) * 2011-10-07 2016-09-20 Eisai R&D Man Co Ltd Pirazolohinolinski derivati kao inhibitori pde9
KR20170132332A (ko) * 2015-04-03 2017-12-01 난트바이오사이언스 인코포레이티드 돌연변이 k-ras 표적 방법 및 조성물
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
LT3328419T (lt) 2015-07-30 2021-11-10 Macrogenics, Inc. Pd-1 surišančios molekulės ir jų panaudojimo būdai
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3377481A1 (en) * 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
PL3377488T3 (pl) 2015-11-19 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3394033T2 (ro) 2015-12-22 2021-04-30 Incyte Corp Compuși heterociclici ca imunomodulatori
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197280A (en) 2016-06-20 2023-06-09 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
KR20190111025A (ko) 2016-12-22 2019-10-01 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
PE20211911A1 (es) 2018-03-30 2021-09-28 Incyte Corp Compuestos heterociclicos como inmunomoduladores
KR20210005106A (ko) * 2018-04-25 2021-01-13 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
JOP20200288A1 (ar) 2018-05-11 2020-11-11 Incyte Corp مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
US20210308123A1 (en) * 2018-08-16 2021-10-07 Innate Tumor Immunity, Inc. Nlrp3 modulators

Also Published As

Publication number Publication date
WO2021211864A1 (en) 2021-10-21
JP2023522202A (ja) 2023-05-29
BR112022020841A2 (pt) 2023-05-02
CA3179692A1 (en) 2021-10-21
PE20230825A1 (es) 2023-05-19
TW202204355A (zh) 2022-02-01
CL2023002090A1 (es) 2023-12-15
US20210355121A1 (en) 2021-11-18
IL297165A (en) 2022-12-01
AU2021254794A1 (en) 2022-12-15
EP4135844A1 (en) 2023-02-22
ECSP22087539A (es) 2023-01-31
CL2022002828A1 (es) 2023-03-31
CN115702025A (zh) 2023-02-14
MX2022012780A (es) 2023-01-18
CO2022016377A2 (es) 2023-02-27

Similar Documents

Publication Publication Date Title
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CR20220363A (es) Compuestos tricíclicos sustituidos
CR20220312A (es) Compuestos tricíclicos sustituidos
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
MX2023007192A (es) Inhibidores de prmt5.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2020010805A (es) Inhibidores de bcl6.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
CR20230286A (es) Inhibidores de prmt5 novedosos
MX2021002805A (es) Terapias de combinacion.
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
PH12021551446A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022004419A (es) Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.